Condition: Lung Non-Small Cell Carcinoma · Stage I Lung Cancer AJCC v8 · Stage II Lung Cancer AJCC v8 · Sponsor: Thomas Jefferson University
This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.
This description comes directly from the study's public registry record.
Tyler Grenda, MD · 215-955-5562 · Tyler.grenda@jefferson.edu
Always discuss trial participation with your own doctor first.
| Abington Memorial Hospital | Abington, Pennsylvania, United States | Recruiting |
| Jefferson Health Northeast | Philadelphia, Pennsylvania, United States | Recruiting |
| Thomas Jefferson University Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
| Asplundh Cancer Pavilion at Jefferson Health | Willow Grove, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05502523